STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Taysha (TSHA) Form 144 Filed for 27,590 Shares, $79K Value

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Taysha Gene Therapies (TSHA) filing a Form 144 notifies intent to sell 27,590 shares of common stock through Maxim Group LLC on 08/21/2025 with an aggregate market value of $79,183.30. The shares were acquired as a RSU award and were vested and settled in stock on 08/21/2025, with the stated consideration being the reporting person’s continued service as an employee. The filing reports 272,794,885 shares outstanding and indicates no securities sold by the reporting person in the prior three months.

Positive

  • Source of shares disclosed: Shares were acquired via an RSU award and were vested and settled in stock on 08/21/2025.
  • Full transaction details provided: Number of shares (27,590), aggregate market value ($79,183.30), broker (Maxim Group LLC), intended sale date (08/21/2025) and shares outstanding (272,794,885) are all specified.

Negative

  • None.

Insights

TL;DR: Routine insider sale notice for vested RSUs; size and timing disclosed, no recent sales reported.

The Form 144 indicates a planned sale of 27,590 shares, arising from a vested RSU award settled in stock the same day. The broker is identified as Maxim Group LLC and the intended sale date is 08/21/2025. The filing complies with Rule 144 disclosure requirements and reports no sales by the reporting person over the prior three months. This appears procedural rather than indicative of sudden material developments.

TL;DR: Disclosure documents an employee's sale of vested equity; includes required certification about material nonpublic information.

The filer certifies they are unaware of undisclosed material adverse information and the form notes the RSU origin and vesting/settlement details. The signature and attestation language required under the form are present. No governance or compliance exceptions are stated in the content provided.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the TSHA Form 144 disclose about the planned sale?

The filing discloses intent to sell 27,590 common shares through Maxim Group LLC on 08/21/2025 with aggregate market value of $79,183.30.

How were the shares acquired according to the Form 144 for TSHA?

The shares were acquired as a RSU award and were vested and settled in stock on 08/21/2025.

Does the Form 144 report any sales by the reporting person in the past three months?

The filing states Nothing to Report for securities sold during the past three months by the reporting person.

What outstanding share count does the Form 144 list for TSHA?

The Form 144 lists 272,794,885 shares outstanding.

Who is the broker handling the proposed sale in the TSHA Form 144?

The broker named in the filing is Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022.
Taysha Gene Therapies, Inc.

NASDAQ:TSHA

TSHA Rankings

TSHA Latest News

TSHA Latest SEC Filings

TSHA Stock Data

1.33B
243.67M
11.15%
94.76%
14.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
DALLAS